These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31139083)

  • 1. Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System.
    Barcelos FC; de Matos GC; da Silva MJS; da Silva FAB; Lima EDC
    Front Pharmacol; 2019; 10():498. PubMed ID: 31139083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious Adverse Drug Reactions and Safety Signals in Children: A Nationwide Database Study.
    Vieira JML; de Matos GC; da Silva FAB; Bracken LE; Peak M; Lima EDC
    Front Pharmacol; 2020; 11():964. PubMed ID: 32848722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential safety signals for antibacterial agents from the Brazilian national pharmacovigilance database (Vigimed/VigiFlow).
    Barbosa LHLA; Silva ARO; Carvalho-Assef APD; Lima EC; da Silva FAB
    Front Pharmacol; 2022; 13():948339. PubMed ID: 36204235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.
    Noseda R; Bedussi F; Gobbi C; Zecca C; Ceschi A
    Cephalalgia; 2021 Jun; 41(7):789-798. PubMed ID: 33435709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use.
    Caster O; Sandberg L; Bergvall T; Watson S; Norén GN
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):1006-1010. PubMed ID: 28653790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.
    Fusaroli M; Salvo F; Begaud B; AlShammari TM; Bate A; Battini V; Brueckner A; Candore G; Carnovale C; Crisafulli S; Cutroneo PM; Dolladille C; Drici MD; Faillie JL; Goldman A; Hauben M; Herdeiro MT; Mahaux O; Manlik K; Montastruc F; Noguchi Y; Norén GN; Noseda R; Onakpoya IJ; Pariente A; Poluzzi E; Salem M; Sartori D; Trinh NTH; Tuccori M; van Hunsel F; van Puijenbroek E; Raschi E; Khouri C
    Drug Saf; 2024 Jun; 47(6):575-584. PubMed ID: 38713346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk for aseptic meningitis after amoxicillin or amoxicillin-clavulanic acid in males: A signal revealed by subset disproportionality analysis within a global database of suspected adverse drug reactions.
    Chandler RE
    Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):389-395. PubMed ID: 30556617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials.
    Beau-Lejdstrom R; Crook S; Spanu A; Yu T; Puhan MA
    Pharmaceut Med; 2019 Aug; 33(4):331-339. PubMed ID: 31933187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of cluster adverse drug events in the spontaneous reporting system of China using a disproportionality filter algorithm.
    Wang M; Ye X; Ruan Y; Xu J; Guo X; Dong D; Feng H; He J
    J Clin Pharm Ther; 2019 Dec; 44(6):952-957. PubMed ID: 31407823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
    Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
    Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
    Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System.
    Crisafulli S; Cutroneo PM; Luxi N; Fontana A; Ferrajolo C; Marchione P; Sottosanti L; Zanoni G; Moretti U; Franzè S; Minghetti P; Trifirò G
    Drug Saf; 2023 Apr; 46(4):343-355. PubMed ID: 36790561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
    Li D; Gou J; Zhu J; Zhang T; Liu F; Zhang D; Dai L; Li W; Liu Q; Qin C; Du Q; Liu S
    Front Pharmacol; 2023; 14():1117391. PubMed ID: 37081961
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase.
    Noseda R; Bonaldo G; Motola D; Stathis A; Ceschi A
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.